![]() | Only 14 pages are availabe for public view |
Abstract Recurrent pregnancy loss leaves a bad impact on patient psyche. It is also not one of the easy tasks to be dealt with in reproductive medicine. RPL is two to three consecutive miscarriages before 20 weeks’ gestation (Regan et al., 2010). About 1–3% of women suffer from this medical condition during their reproductive period (Toth et al., 2010). Until know up to 50% of RPL cases the definite underlying cause or pathophysiological mechanisms is still not determined (Karvela et al., 2008). Nowadays, obesity is a major health burden on governments and becoming a global problem across the world (Anonymous, 2001). It is documented that obese mothers act like a risk factor for adulthood obesity in their new coming offspring (Parsons et al., 2001). Obesity promotes to a poor pregnancy outcome, for example spontaneous or unexplained intrauterine fetal death (Froen et al., 2001) Poor outcome that affects the mother and the offspring due to pre pregnancy maternal obesity for example diabetes, hypertension and many thrombophlic problems. Off spring of many obese mothers are more liable to face difficulties during birth, macrosomia, and prenatal death (Nuthalapaty and Rouse, 2004). Gene mutations can be turned on by any change in the home environment and also the external environment in which human grow (Lobo, 2008).Many hormones depend on their mechansime on Jinas Kinas, JAK-signal transducers and activators of transcription STAT which greatly affects fat cell function. In Obesity leptin and IL-6 increase in obese women continually activating intracellular JAK-STA3. Leptin works mainly on central nervous system, IL-6 works on peripheral organs and they can switch targets. Continuous JAK-STAT3 activation by leptin and IL-6 lead to the increased expression of the negative regulator SOCS3. SOCS3 in then have a negative feedback on leptin and IL-6 signaling regulating it plus antagonizing insulin action which leads to gaining more weight and insulin resistance (Wunderlich et al., 2013). JAK2 a tyrosine kinase has main role in signal transduction in many hematopoietic growth factor receptors. The(V617F) mutation is due to valine-to-phenylalanine substitution at position 617this mutation happened due to a gain-of-function mutation in the gene encoding the Janus kinase2 (JAK2) leading to continues activation tyrosine kinase and mutation, V617F, in the JH2 pseudo-kinase domain of JAK2 gene is responsible for offspring loss. This mutation was found in patients suffering from thrombocythemia. Thrombocythemia during pregnancy leads to sudden pregnancy loss and decreased percentage in live rates (Randone et al., 2011; El-magraby and Bedwey, 2012). Thrmobophilia leads to thrombosis of the utero-placental circulation due to cascading that ocurrs in haemostatic response. Disturbance and decrease in placental perfusion may lead to recurrent pregnancy loss (Lockwood, 2011).This case control study included 250 female patients. The study group consists of 150 female patients with history of recurrent pregnancy loss for two consecutive times or more, aged (20-34) and having a body mass index of >24.9. The control group consists of 100 aged matched women having normal body mass index and as well as having a minimum of one live child birth and no past history of previous pregnancy loss or uncomplicated pregnancy. All participants underwent a standard diagnostic workup including Systemic Pedigree analysis, serum progesterone, FSH and LH, anticardiolipin (IgM and IgG), couple karyotypying and abdominal ultrasound scan. All women were investigated for the mutations by using the allele-specific multiplex PCR technique to genotype all participants in the study. Results Jak2v617 mutation was found in cases (9.3%) while no jak2 v617f mutation was found among the control group, p< 0.001). Patients in case group were obese with a mean BMI of (30.9 ±4.3) vs mean BMI control group (22.4 ±1.1, p<0.001).History of live birth in case group (42.7%) vs 100 %in control, P< (0.001). consanguineous marriages were positive (57.4% vs 13 %, p<0.001). Only 13 patients of the case group experienced pregnancy loss after 12 weeks of gestation while the rest of the case group (137) including 14 patients who were positive for jak2 v617f mutation experienced pregnancy loss before 12 weeks of gestation (p <0.06). |